A meta-analysis of 8 studies found GLP-1 receptor agonists were associated with a 59% lower risk of hepatocellular carcinoma compared to insulin or no GLP-1RA, but showed no significant difference versus metformin or DPP-4 inhibitors.
59% lower HCC riskGLP-1 receptor agonists were associated with a 59% lower hepatocellular carcinoma risk compared to insulin therapy in diabetic patients
What the researchers found
GLP-1RAs vs insulin/no GLP-1RA: pooled HR 0.41 (CI 0.28-0.55), with considerable heterogeneity (I²=74%). GLP-1RAs vs metformin: HR 0.99 (not significant). GLP-1RAs vs DPP-4 inhibitors: HR 1.05 (not significant). GLP-1RAs vs sulfonylureas: HR 0.78 (CI 0.65-0.93).
Why it matters
Liver cancer is increasing globally, driven partly by the metabolic liver disease epidemic in diabetic patients. If GLP-1 drugs reduce HCC risk — even partly through improved liver health — this adds another compelling reason to prescribe these peptide medications for at-risk diabetic patients.
The numbers in context
Not specified in abstract — meta-analysis of available studies.
How the study worked
Systematic review and meta-analysis of PubMed, EMBASE, and Web of Science through August 2024. Eight studies evaluating HCC incidence in T2DM patients on GLP-1RAs vs other therapies included. Random-effects model used for pooled hazard ratios. Heterogeneity assessed via I² statistic.
Who was studied
T2DM patients with chronic liver conditions from observational studies
What this study cannot tell us
Considerable heterogeneity (I²=74%). Observational studies are subject to confounding — GLP-1RA users may differ systematically from insulin users. No randomized controlled trial data. The comparison to metformin showing no difference suggests the benefit may not be GLP-1-specific. Publication bias not fully assessed.
How to read the evidence
Rated moderate: systematic review with meta-analysis of 8 studies, but limited by observational data, considerable heterogeneity, and inability to establish causation.
When this study was published
Published in 2024. Represents the first meta-analysis specifically examining GLP-1RA and liver cancer risk.
The bigger picture
The finding that GLP-1 drugs reduce HCC risk compared to insulin (but not metformin) raises an important question: is this a direct protective effect of GLP-1 agonists, or does insulin itself increase cancer risk? Either way, it supports preferring GLP-1 peptide drugs over insulin escalation in diabetic patients at liver cancer risk.
Questions still open
- Does semaglutide's greater weight loss and liver fat reduction translate to greater HCC protection than other GLP-1RAs?
- Is the HCC risk reduction mediated through MASH/NAFLD improvement or through direct anti-tumor effects?
- Should GLP-1RAs be preferred over insulin specifically for diabetic patients with liver disease or NAFLD?
Common questions
Can GLP-1 drugs reduce liver cancer risk?
Should diabetic patients with liver disease take GLP-1 drugs?
Read the original research
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.
BMC endocrine disorders, 24(1), 246
Citation
Shabil, Muhammed; Khatib, Mahalaqua Nazli; Ballal, Suhas; Bansal, Pooja; Tomar, Balvir S; Ashraf, Ayash; Kumar, M Ravi; Sinha, Aashna; Rawat, Pramod; Gaidhane, Abhay M; Sah, Sanjit; Daniel, Afukonyo Shidoiku; Yappalparvi, Ambanna; Bushi, Ganesh. (2024). Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.. BMC endocrine disorders, 24(1), 246. https://doi.org/10.1186/s12902-024-01775-2